
FibroGen (FGEN) Stock Forecast & Price Target
FibroGen (FGEN) Analyst Ratings
Bulls say
FibroGen Inc. is focused on advancing its R&D pipeline with significant revenue generated from collaboration agreements, primarily in Europe and Japan. The anticipated extension of the company's cash runway, bolstered by a recent $75 million cash injection from the sale of FibroGen China to AstraZeneca, supports its financial health amid challenging market conditions. Additionally, the potential for FG-3246 to demonstrate a rPFS benefit of 12 months or more positions the company favorably against competitors, enhancing its prospects for becoming a market leader in therapeutics for serious medical conditions.
Bears say
FibroGen Inc. faces significant challenges that could negatively impact its stock performance, primarily stemming from the risks associated with clinical trials, which could yield failed or inconclusive results. Additionally, the company's reliance on collaboration agreements for revenue generation raises concerns about its ability to secure adequate funding necessary for product development, potentially leading to dilutive capital raises. Compounding these issues is the risk of lack of commercial success for its therapeutics and the threat of delisting, which could further undermine investor confidence.
This aggregate rating is based on analysts' research of FibroGen and is not a guaranteed prediction by Public.com or investment advice.
FibroGen (FGEN) Analyst Forecast & Price Prediction
Start investing in FibroGen (FGEN)
Order type
Buy in
Order amount
Est. shares
0 shares